Repositioning Candidate Details
| Candidate ID: | R1335 |
| Source ID: | DB11110 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Magnesium citrate |
| Synonyms: | Magnesium citrate; Magnesium dicitrate; Trimagnesium citrate; Trimagnesium dicitrate |
| Molecular Formula: | C12H10Mg3O14 |
| SMILES: | [Mg++].[Mg++].[Mg++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O |
| Structure: |
|
| DrugBank Description: | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. |
| CAS Number: | 3344-18-1 |
| Molecular Weight: | 451.113 |
| DrugBank Indication: | Magnesium citrate has been used in bowel preparations prior to a colonoscopy as a cathartic agent. It is also used in over-the-counter products to relieve occasional constipation. Magnesium citrate can be one of the forms used for the administration of dietary supplements. |
| DrugBank Pharmacology: | The onset of action can be as early as 30 minutes after administration with a mean onset time of approximately 2 hours and a maximum action of 4 hours. The effect of magnesium citrate is highly dependent on the individual's hydration status. |
| DrugBank MoA: | It mainly works through its property of high osmolality which will draw large amounts of fluid into the colonic lumen. There is also a possible stimulation of fluid excretion by cholecystokinin release and activation of muscle peristalsis. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|